January 31, 2017
Teva launches two asthma products in 2017 to compete with GSK
Teva’s two asthma treatments for patients older than 12 has been approved by the US Food and Drug Administration (FDA).
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
US Court rules in Mylan’s favor, another decision against Teva
Israel’s largest drugmaker, Teva, has came up short yet again against a US courts regarding patent infringement cases.
January 31, 2017
European Commission OK’s Novartis’s tuberous sclerosis complex drug
European Commission has approved Novartis’s Votubia (everolimus) dispersible tablets as an adjunctive treatment for patients aged two years and older whose…
January 31, 2017
TiGenix kicks off Sepcell trial to test new pneumonia treatment
TiGenix has enrolled the first patient and treated in a Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
January 30, 2017
Allergan’s to update label on its antibiotic Avycaz
Allergan has ensured permit to update the label for its Avycaz with new data from two third phase clinical trials, about treatining patients with certain complicated urinary tract infections (UTI).
January 30, 2017
CHMP recommends Pfizer’s rheumatoid arthritis drug for European approval
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended Pfizer’s Xeljanz (tofacitinib citrate)…
January 30, 2017
Another USA laswusit against Teva, Aralez charges for 4 patent infringements
Aralez Pharmaceuticals will press charges against Teva in the USA for infringing four patents.
January 30, 2017
InnovaDerma appoints acquisition specialist as a Non-Executive Director
InnovaDerma has appointed Kieran Callan as a Non-Executive Director with immediate effect, succeeding Garry Lemair who stepped down from the…
January 30, 2017
Drugmaker Novo Nordisk bets $145 million on post-Brexit UK science
Novo Nordisk, the world’s top maker of diabetes drugs, is investing 115 million pounds ($145 million) in a new research center in Britain, undeterred by Brexit.